Deciding to stop taking Suboxone is a significant step. For most people, Suboxone was prescribed as part of a medication-assisted treatment (MAT) plan for opioid dependency, and stopping it can feel just like or even more intense than other opioids. The withdrawal process is real, it is prolonged, and it can be deeply discouraging without the right information and support. This article explains what Suboxone withdrawal involves, why it happens, and what options exist, including a treatment approach that targets the biological root of dependency rather than managing symptoms alone.
What Is Suboxone?
Suboxone is an FDA-approved MAT prescription opioid combining buprenorphine and naloxone in a 4:1 ratio. Buprenorphine is a partial opioid agonist, meaning it activates opioid receptors to suppress withdrawal symptoms and cravings. Naloxone is included to deter misuse; when taken sublingually as prescribed, it is not meaningfully absorbed.
Suboxone is widely prescribed for opioid use disorder (OUD) and can serve an important purpose. However, its use continues the physical dependency by maintaining opioid receptor activation, which must be carefully addressed when a person decides to stop.
QUICK FACTS: SUBOXONE
- Drug Type
- MAT medication; partial opioid agonist/antagonist combination (buprenorphine/naloxone)
- Withdrawal Onset
- Within 24-72 hours after last dose (delayed due to buprenorphine's long half-life of approximately 38 hours)
- Withdrawal Peak
- Days 3-7 after last dose (physical symptoms most intense at approximately 72 hours)
- Withdrawal Duration
- Acute phase: 7-20 days; psychological symptoms (depression, cravings) may persist 1 month or longer; post-acute withdrawal syndrome (PAWS) may continue for 6 months or more
Why Does Suboxone Withdrawal Happen?
Suboxone withdrawal is a direct consequence of how opioids interact with the central nervous system (CNS). Withdrawal occurs because buprenorphine continues the same opioid-dependent state rather than resolving it. Over time, the CNS adapts to the continuous activation of opioid receptors by buprenorphine. Two changes continue simultaneously: the body's natural endorphin production is still suppressed, and the number of opioid receptors increases as the body attempts to compensate. When Suboxone is discontinued, the now-enlarged number of receptors is left without adequate stimulation, and endorphin production remains suppressed - creating a neurochemical deficit that the body experiences as withdrawal.
Several factors influence the severity of Suboxone withdrawal for any individual. Duration of use plays a central role. The longer Suboxone has been taken, the more entrenched the CNS adaptation. Dose level matters just as much, with higher doses producing deeper endorphin- opioid receptor imbalance. Liver function affects how efficiently buprenorphine is metabolized and cleared from the body, directly influencing how long withdrawal lasts. Finally, metabolic ability, the overall speed at which a person's body processes substances, determines both onset timing and the intensity of the withdrawal experience.
Suboxone Withdrawal Symptoms
Suboxone withdrawal symptoms are driven by the same endorphin- opioid receptor imbalance as other opioid withdrawal, but the timeline is extended due to buprenorphine's long half-life. Symptoms build gradually over days rather than hours, peak later, and persist longer than short-acting opioids. The withdrawal experience is often described as less intense but more drawn out.
Early Symptoms
- Fever and chills
- Profuse sweating
- Severe muscle, bone, and joint pain
- Nausea, vomiting, and diarrhea
- Abdominal cramping
- Headache
- Runny nose and watery eyes
- Dilated pupils
- Insomnia (particularly prominent and persistent with Suboxone)
- Lethargy and fatigue
- Intense opioid cravings
- Anxiety and restlessness
- Irritability and agitation
- Mood swings
- Difficulty concentrating
Symptoms Peak
- Severe muscle and bone pain at maximum intensity
- Persistent nausea, vomiting, and diarrhea with risk of dehydration
- Continuous insomnia
- Heightened anxiety and agitation
- Intense, unrelenting opioid cravings
- Profuse sweating and chills
- Extreme fatigue and lethargy
Acute Symptoms Subsiding
- Gradual reduction in muscle and joint pain
- Decreasing nausea and GI disturbance
- Slowly improving sleep (though disturbances persist)
- Emerging depression as physical symptoms fade
- Anhedonia (inability to feel pleasure)
- Cravings remain persistent and intense
- Cognitive difficulties and difficulty concentrating
- Intermittent anxiety
- Low energy and emotional blunting
Post-Acute Withdrawal Syndrome (PAWS)
- Persistent depression (can be severe)
- Prolonged insomnia and sleep disturbances
- Intermittent anxiety, including generalized anxiety disorder-like episodes
- Mood instability and unpredictable mood swings
- Anhedonia and emotional blunting
- Cognitive difficulties (attention deficit, difficulty concentrating)
- Persistent opioid cravings
- Low energy and indifference
Post-acute withdrawal syndrome (PAWS) refers to a cluster of predominantly psychological symptoms that persist well beyond the acute withdrawal phase. With Suboxone, PAWS is documented in peer-reviewed literature and reflects the ongoing dysregulation of the endorphin- opioid receptor system. The body has not yet restored its natural equilibrium. Symptoms occur intermittently and can last from 6 months to more than a year, representing the period of highest relapse risk. PAWS data specific to Suboxone remains an emerging area of research, though its occurrence following buprenorphine treatment for opioid use disorder has been confirmed in published case reports.
Suboxone Withdrawal Timeline
Because buprenorphine has an exceptionally long half-life of approximately 38 hours, the withdrawal timeline is significantly prolonged compared to short-acting opioids. Since buprenorphine leaves the opioid receptors very slowly, withdrawal takes longer to start, and once it begins, symptoms can last for an extended period.
Withdrawal begins within 24-72 hours of the last dose. The delayed onset - compared to short-acting opioids like heroin, where symptoms begin within 8-12 hours - is a direct result of buprenorphine's approximately 38-hour half-life. Initial symptoms include fever, headache, muscle aches, nausea, vomiting, diarrhea, sweating, insomnia, anxiety, and the onset of intense opioid cravings.
Physical symptoms remain intense and begin their slow decline from peak severity. Flu-like symptoms, body aches, and insomnia persist throughout this phase. Mood swings, anxiety, and irritability are prominent. Cravings remain at peak intensity.
Physical symptoms largely resolve by day 10 for most patients, though some experience them for up to 20 days. As physical symptoms fade, psychological symptoms intensify - depression, anhedonia, agitation, and persistent cravings become the dominant complaints. This phase is often the most psychologically difficult.
Severe depression and intense cravings persist, which is identified as the highest-risk for relapse. Buprenorphine's long receptor occupancy means the endorphin production takes longer to restore. This extended PAWS phase is why most Suboxone taper attempts fail. The biological imbalance remains unresolved for months, and patients eventually return to Suboxone or other opioids to escape the persistent discomfort.
Common Approaches to Quitting Suboxone
Stopping Suboxone is not straightforward, and several approaches exist, all options focusing on detoxification and symptom mitigation rather than resolution of the underlying issue. Each is described below, along with its documented limitations.
Supervised Dose Tapering
The most widely practiced clinical approach involves a physician creating an individualized schedule to reduce the buprenorphine dose incrementally over time. Each reduction step is typically no more than 25%, with adequate time between steps to allow the body to adjust.
Does not address the underlying dysregulation of the endorphin- opioid receptor system. A NIDA-funded multi-site clinical trial found that only 12-13% of participants provided opioid-free results 3 months post-taper, regardless of whether they followed a shorter or longer schedule. Because the neurochemical imbalance driving cravings remains untreated, relapse risk persists even after a carefully managed taper.
Cold Turkey
Cold turkey involves stopping Suboxone entirely without a tapering schedule or medical supervision. It is chosen for its accessibility, no prescription, no clinic, no schedule required. No clinical guideline recommends this approach for Suboxone. Many patients resort to unadvised workarounds, including the so-called Suboxone spit trick in an attempt to lower their effective dose on their own.
Does not address the underlying dysregulation of the endorphin- opioid receptor system. Abrupt quitting significantly intensifies withdrawal symptoms because the sudden lack of opioid receptor activation leaves the now-overpopulated opioid receptor system completely unstimulated. Risks include severe dehydration from vomiting and diarrhea, electrolyte imbalance, exacerbation of underlying depression, and high relapse risk. Post-detox relapse with reduced opioid tolerance carries additional risk of Suboxone overdose and death.
Switching Medications
Some clinicians transition patients from Suboxone to methadone (a full opioid agonist) for patients who cannot tolerate buprenorphine tapering. Methadone transition requires enrollment in a federally certified opioid treatment program.
Does not address the underlying dysregulation of the endorphin-opioid receptor system. The body cannot begin endorphin restoration while MAT medications occupy opioid receptors. Transitioning to methadone substitutes one opioid dependency for another. Methadone is a full opioid agonist, meaning it continues opioid receptor activation and maintains the same dependency as to Suboxone, rather than resolving it. Eventually, the patient will still withdraw from methadone as well.
Inpatient Medical Detox
Medically supervised inpatient detoxification provides supportive care, including medications to manage symptoms, nausea, and sleep disruption, in a hospital or residential facility. It is often combined with counseling and behavioral support.
Does not address the underlying dysregulation of the endorphin-opioid receptor system. Inpatient detox manages acute withdrawal symptoms but does not treat the neurobiological root cause of dependency. In a prospective study of patients following inpatient opioid detoxification, 91% relapsed after discharge, with 59% returning to use within the first week (Smyth et al., 2010). PAWS symptoms are not addressed by standard detox protocols.
Why Traditional Approaches Don't Lead to Lasting Results
None of the traditional approaches to quitting Suboxone address the underlying biological condition driving dependency and none produces lasting results at a meaningful rate.
Passive Restoration: Cold Turkey, Tapering, and Inpatient Detox
Cold turkey, supervised tapering, and inpatient detox all rely on the same fundamental mechanism: time. The assumption is that if the drug is removed from the body, abruptly or gradually, the CNS will eventually restore its natural endorphin- opioid receptor equilibrium on its own. Passive restoration is an insufficient strategy because the elevated receptor demand and reduced endorphin production caused by long-term opioid use, including Suboxone, do not self-correct quickly or reliably. The body is left to recover a complex neurochemical balance over months, during which cravings remain intense, depression deepens, and relapse risk is at its highest. PAWS can extend this period of vulnerability for months or longer after the last dose.
Substitution: Switching to Another Prescription Opioid
Transitioning from Suboxone to methadone or another prescription opioid does not resolve dependency, it transfers it. The body cannot begin endorphin restoration while MAT medications occupy opioid receptors. Methadone is itself a full opioid agonist with a complex dependency profile, and most patients who switch never successfully taper off. The neurochemical imbalance that defines opioid dependency remains fully intact, simply sustained by a different prescription opioid rather than resolved.
How ANR Treats Suboxone Dependency at the Source
ANR (Accelerated Neuro-Regulation) is a comprehensive medical treatment developed specifically for opioid dependency. Where every traditional approach either waits for the body to recover passively or substitutes one opioid for another, ANR directly targets the biological root cause: the dysregulation of the endorphin- opioid receptor system caused by prolonged opioid exposure.
25,000+
Patients treated globally
9 out of 10
Patients remain opioid-free long term
Rather than managing Suboxone withdrawal symptoms, ANR works to restore the body's equilibrium - recalibrating the opioid receptor system to its pre-dependency state so that the body no longer requires external opioid stimulation. ANR follows a structured four-stage framework. Preparation: Treatment begins right away. The medical team conducts pre-admission clinical evaluations, assessing each patient's unique dependency profile, medical history, drug use patterns, and any co-morbidities. This individualized assessment ensures the treatment protocol is tailored specifically to each individual patient, and they can begin preparation for the hospitalization Regulation: This phase involves the hospital-based procedure itself. The entire hospital stay lasts approximately 36 hours, with 4-6 hours of the procedure itself under sedation. During this time, the endorphin- opioid receptor modulation occurs. The patient does not feel withdrawal symptoms. Stabilization: Patients receive 3 days of post-discharge in-person follow-ups. Any temporary discomfort during this period is like bouncing back from surgery; discomfort is healing, not illness. The endorphin- opioid receptor system is actively adjusting and beginning to function without dependence on external opioids. Optimization: Over the following 6-12 months, patients focus on strengthening their long-term outcome through nutrition, physical activity, mental engagement, and daily naltrexone, a non-opioid receptor blocker that supports receptor regulation without creating dependency.
STAGE 1
Preparation
STAGE 2
Regulation
STAGE 3
Stabilization
STAGE 4
Optimization
Over 25,000 patients have been treated with ANR globally. 9 out of 10 patients remain opioid-free long-term - a result none of the conventional approaches come close to matching.
Every traditional approach discharges patients while the endorphin- opioid receptor system remains dysregulated, leaving them to endure weeks or months of PAWS symptoms, including severe depression, persistent cravings, insomnia, and emotional blunting, entirely on their own. ANR resolves PAWS during hospitalization and stabilization. Patients are not left to manage a prolonged neurochemical recovery after discharge – the system has been restored, not just cleared of the drug. For people stopping Suboxone, who face some of the most prolonged and psychologically demanding PAWS of any opioid, this distinction is significant.
ANR was developed by Dr. Andre Waismann, Founder of ANR Clinic, who originally pioneered rapid detox, recognized its fundamental limitations, and spent years creating ANR as its scientifically superior successor.
Frequently Asked Questions About Quitting Suboxone
How long does Suboxone withdrawal last?
Acute Suboxone withdrawal typically begins within 24-72 hours of the last dose and lasts between 7 and 20 days for most patients, with physical symptoms largely resolving by day 10. Psychological symptoms, particularly depression and opioid cravings, can persist at the one-month mark and represent the highest-risk period for relapse. Post-acute withdrawal syndrome (PAWS) may follow, with intermittent symptoms lasting 6 months or longer. The prolonged timeline is directly related to buprenorphine's long half-life of approximately 38 hours.
Why is Suboxone withdrawal so difficult to get through?
Suboxone withdrawal is particularly challenging because buprenorphine has an exceptionally high binding affinity for opioid receptors and a very long half-life. This means the CNS adapts deeply over time, and when the drug is removed, the receptor system is left significantly dysregulated. Physical symptoms are prolonged compared to short-acting opioids, and the psychological phase, dominated by depression, anhedonia, and persistent cravings, often intensifies as physical symptoms ease. Without treatment that addresses the underlying endorphin- opioid receptor imbalance, the body is left to recover passively over a very long period.
Can you taper off Suboxone on your own?
Tapering should always be done under medical supervision. Self-managed dose reduction carries significant risks, including miscalculated reductions that trigger more severe withdrawal, difficulty maintaining a schedule during cravings, and high relapse risk. Even under clinical supervision, a NIDA-funded multi-site trial found that only 12-13% of patients provided opioid-free results at 3 months post-taper, highlighting that even well-managed tapering does not reliably address the underlying neurochemical condition. Patients managing underlying pain while tapering can also benefit from learning how long after taking Suboxone they can take pain medicine.
Is Suboxone withdrawal dangerous?
Suboxone withdrawal is not typically life-threatening for otherwise healthy individuals, but it carries real medical risks that require attention. Severe nausea, vomiting, and diarrhea can cause dangerous dehydration and electrolyte imbalance. The psychological phase, particularly the severe depression and anhedonia that dominate weeks 2-4 - represents a serious mental health risk and the period of highest relapse likelihood. Medical supervision while quitting Suboxone is strongly recommended regardless of the approach chosen.
Can stopping Suboxone lead to long-term depression?
Yes. Depression is one of the most prominent and persistent features of Suboxone withdrawal. As physical symptoms subside, depression and anhedonia (the inability to feel pleasure) intensify, reflecting the ongoing dysregulation of the endorphin- opioid receptor system. For some individuals, this psychological state can persist for months as part of PAWS. Approaches that do not address the underlying dysregulation leave patients to manage this depression passively, with no biological resolution in sight. ANR Treatment addresses this directly through endorphin-receptor modulation, eliminating withdrawal completely.
What is the cost of ANR Treatment for Suboxone dependency?
ANR Treatment is priced at $21,500. This covers the comprehensive four-stage treatment process – Preparation, Regulation, Stabilization, and Optimization – including pre-admission evaluations, the hospital-based procedure, 3 days of post-discharge in-person follow-ups, and the 6-12 month optimization support period. Because it is an elective medical procedure, it is not covered by insurance, but we understand that cost shouldn't be a barrier to recovery. Financing options are available. Visit anrclinic.com/financing to learn more.
Related Articles
Sources / References
- Kumar, R., Viswanath, O., & Saadabadi, A. (Updated June 8, 2024). "Buprenorphine." StatPearls [Internet]. National Library of Medicine / NCBI Bookshelf. https://www.ncbi.nlm.nih.gov/books/NBK459126/
- Tripathi, B.M., Hemaraj, P., & Dhar, N.K. (1995). "Buprenorphine Withdrawal Syndrome." Indian Journal of Psychiatry, 37(1), 23. PMC: https://pmc.ncbi.nlm.nih.gov/articles/PMC2970944/
- Ling, W., Hillhouse, M., Domier, C., et al. (2009). "Buprenorphine tapering schedule and illicit opioid use." Addiction, 104(2), 256-265. PMC: https://pmc.ncbi.nlm.nih.gov/articles/PMC3150159/
- Waismann, A., Kabemba, A., Medowska, O., Salzman, R., Philpott, C., & Patel, M.M. (2023). "Hemodynamic and Pulmonary Safety Profile of the Accelerated Neuroregulation Procedure." NeuroRegulation, 10(4), 253-259. https://doi.org/10.15540/nr.10.4.253
- Post-acute Withdrawal Syndrome case report. (2023). PubMed/NCBI. PMID 36731102. https://pubmed.ncbi.nlm.nih.gov/36731102/
- Substance Abuse and Mental Health Services Administration (SAMHSA). (2021). "2021 National Survey on Drug Use and Health (NSDUH)." https://www.samhsa.gov/data/report/2021-nsduh-annual-national-report
- Smyth, B.P., Barry, J., Keenan, E., & Ducray, K. (2010). "Lapse and relapse following inpatient treatment of opiate dependence." Irish Medical Journal, 103(6), 176-179. PMID: 20669601. https://pubmed.ncbi.nlm.nih.gov/20669601/